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Andrew F. Olshan1,2 and Melissa A. Troester1,2*Abstract
Background: Spatial heterogeneity in biomarker expression may impact breast cancer classification. The aims of
this study were to estimate the frequency of spatial heterogeneity in biomarker expression within tumors, to
identify technical and biological factors contributing to spatial heterogeneity, and to examine the impact of
discordant biomarker status within tumors on clinical record agreement.
Methods: Tissue microarrays (TMAs) were constructed using two to four cores (1.0 mm) for each of 1085 invasive
breast cancers from the Carolina Breast Cancer Study, which is part of the AMBER Consortium.
Immunohistochemical staining for estrogen receptor (ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2) was quantified using automated digital imaging analysis. The biomarker status for
each core and for each case was assigned using clinical thresholds. Cases with core-to-core biomarker discordance
were manually reviewed to distinguish intratumoral biomarker heterogeneity from misclassification of biomarker
status by the automated algorithm. The impact of core-to-core biomarker discordance on case-level agreement
between TMAs and the clinical record was evaluated.
Results: On the basis of automated analysis, discordant biomarker status between TMA cores occurred in 9 %,
16 %, and 18 % of cases for ER, PR, and HER2, respectively. Misclassification of benign epithelium and/or ductal
carcinoma in situ as invasive carcinoma by the automated algorithm was implicated in discordance among cores.
However, manual review of discordant cases confirmed spatial heterogeneity as a source of discordant biomarker
status between cores in 2 %, 7 %, and 8 % of cases for ER, PR, and HER2, respectively. Overall, agreement between
TMA and clinical record was high for ER (94 %), PR (89 %), and HER2 (88 %), but it was reduced in cases with
core-to-core discordance (agreement 70 % for ER, 61 % for PR, and 57 % for HER2).
Conclusions: Intratumoral biomarker heterogeneity may impact breast cancer classification accuracy, with
implications for clinical management. Both manually confirmed biomarker heterogeneity and misclassification of
biomarker status by automated image analysis contribute to discordant biomarker status between TMA cores. Given
that manually confirmed heterogeneity is uncommon (<10 % of cases), large studies are needed to study the
impact of heterogeneous biomarker expression on breast cancer classification and outcomes.
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Heterogeneity in biomarker expression between tumors
is the basis for breast cancer subtyping and precision
medicine [1]. However, intratumoral heterogeneity,
often reflecting spatial heterogeneity of biomarker ex-
pression within a single tumor, has important implica-
tions for accurate tumor classification, and it may
impact both epidemiologic research [2] and clinical
decision-making [3].
Approximately 10–20 % of tumors are found to have
disagreement in estrogen receptor (ER), progesterone re-
ceptor (PR), and human epidermal growth factor recep-
tor 2 (HER2) status upon repeat assay, as assessed by
studies examining interlaboratory agreement rates [4–6].
A variety of technical factors contribute to lack of inter-
laboratory agreement, including differences in antibody
or assay type; level of laboratory experience; and tumor
sampling, fixation, and storage protocols [4, 7–14]. In
addition to these technical factors, repeat assays are
commonly carried out using a separate tumor block and
therefore may test a different area of the tumor, suggesting
that spatial heterogeneity of biomarker expression may
also contribute to discordance [15]. However, the fre-
quency and sources of intratumoral ER, PR, and HER2
heterogeneity have not been evaluated in population-
based studies.
Using tissue microarrays (TMAs) comprising two to four
tumor cores for each of 1085 cases from the Carolina
Breast Cancer Study (CBCS) in the African American
Breast Cancer Epidemiology and Risk (AMBER) Consor-
tium, we identified cases with core-to-core discordance in
ER, PR, and HER2 status using automated digital image
analysis. Discordant cases were manually reviewed to iden-
tify technical and biological factors contributing to variabil-
ity in biomarker expression. We estimated the frequency of
intratumoral ER, PR, and HER2 heterogeneity among
biomarker-positive cases and evaluated the impact of bio-
marker discordance on case-level ER, PR, and HER2 status
agreement between TMAs and the clinical record.
Methods
Study population
The AMBER Consortium, comprising the Black Women’s
Health Study, the Women’s Circle of Health Study, the
Multi-Ethnic Cohort Study, and the CBCS, was formed to
identify genetic and nongenetic factors associated with
specific breast cancer subtypes [16]. Standardization of
staining and scoring protocols for classification of invasive
breast cancer subtypes is a major objective of this collab-
orative study [17]. For our present analyses, we used phase
III of CBCS, a population-based, case-only study con-
ducted in North Carolina between 2008 and 2013 [18].
The study was approved by the Office of Human Research
Ethics at the University of North Carolina at Chapel Hill,and written informed consent was obtained from each
participant.
Clinical ER, PR, and HER2 status was abstracted from
medical records. Cases noted in the medical records to
have weak or borderline ER and PR expression were
classified as ER-positive and PR-positive, respectively, ac-
cording to current guidelines [19]. Paraffin-embedded
tumor blocks were requested from participating path-
ology laboratories for each case, and study pathologists
marked hematoxylin and eosin (H&E)-stained slides to
indicate areas enriched for invasive breast cancer for cor-
ing. TMAs were constructed from 1.0-mm cores, and these
comprised 1238 invasive breast cancer cases (n = 600
African American and n = 638 non-African American).
Sections from the top and bottom of eachTMA block were
stained with H&E and reviewed by study pathologists to
ensure that only TMA cores with top and bottom tumor
in addition to sufficient tumor cellularity (≥50 tumor cells
per core) were included in our analysis. We excluded cases
that were missing clinical ER, PR, or HER2 status (n = 76),
as well as cases represented by only one evaluable core on
our TMAs (n = 66) as core-to-core discordance could not
be assessed. Finally, we excluded cases with cores derived
from multiple tumor blocks (from either single or multiple
tumors; n = 11), leaving us with 1085 cases included in the
present analysis. A comparison of CBCS phase III cases on
TMAs (41 % of all cases in CBCS phase III) with those not
on TMAs showed no differences with respect to race or
clinical ER, PR, or HER2 status. However, phase III cases
on TMAs were older and more likely to be postmeno-
pausal, and they had higher combined grade but lower
stage and smaller tumor size.
Classification of central ER, PR, and HER2 status using
tissue microarrays
Detailed methods for immunohistochemical (IHC) stain-
ing of ER, PR, and HER2 in CBCS have been described
elsewhere [17]. Of the 1085 cases included in the present
analysis, 685 cases (63 %) had 4 cores, 287 cases (27 %)
had 3 cores, and 113 cases (10 %) had 2 cores for ER.
The distribution of numbers of cores per case was simi-
lar for PR and HER2. Automated digital image analysis
of IHC staining was performed using a Genie classifier
(Aperio Technologies, Vista, CA, USA) and the Nuclear
v9 algorithm (for ER and PR) or Membrane v9 algorithm
(for HER2) (Aperio Technologies, Vista, CA, USA); this
analysis is described in more detail in our previous pub-
lication [17]. Core-to-case collapsing to assign case-level
biomarker status was carried out using a tumor
cellularity-weighted approach, as previously described
[17]. Briefly, the weighted average of percent positivity
was calculated by summing the product of percent posi-
tivity and core weight across all cores per case. Core
weight was defined as the number of tumor nuclei in a
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across all cores for that case. A 1 % threshold for ER
and PR positivity [19] was subsequently applied to define
dichotomous positive/negative case-level status for ER
and PR. Case-level HER2 status was defined as positive
(3+; ≥10 % of tumor cells staining at the 3+ intensity
level), equivocal (2+; <10 % of tumor cells staining at the
3+ intensity level and ≥10 % of tumor cells staining at the
2+ intensity level), or negative (0/1+; all other cases). We
reported previously that these automated scoring methods
showed very high agreement with manual review by study
pathologists and with the clinical record [17].Identification of technical and biological sources of ER,
PR, and HER2 discordance
Discordant cases (i.e., cases with discordant biomarker
status between TMA cores) were manually reviewed by
a breast pathologist (JG) to identify those in which dis-
cordance was caused by spatial heterogeneity of bio-
marker expression and those in which discordance was
caused by misclassification by the automated algorithm.
We restricted this manual evaluation to discordant cases
with positive case-level biomarker status (≥1 %), because
biomarker discordance between cores in negative cases
was due to random variation around the 1 % threshold
used to define case status. Only one ER-negative case
showed >10 % variation in ER status between cores
(Additional file 1: Figure S1). Manual assessment of intra-
tumoral HER2 heterogeneity was performed for discord-
ant cases with at least one 3+ core, since heterogeneity
within HER2-negative cases (i.e., cases with only 0/1+ and
2+ cores) is less clinically relevant.Impact of core-to-core discordance in biomarker status
on case-level agreement with the clinical record
We identified cases with discordant biomarker status be-
tween cores using dichotomous ER and PR status (i.e.,
<1 %, ≥1 %) and three-category HER2 status (i.e., 0/1+, 2+,
3+). We also explored ER and PR discordance using a
10 % threshold. The frequency of discordance did not dif-
fer by race for any biomarker (data not shown). Median
tumor cellularity was compared between cases with dis-
cordant versus concordant biomarker status between
cores using rank-sum tests, and chi-square tests were used
to compare rates of biomarker discordance among cases
with two, three, and four TMA cores. Cohen’s kappa sta-
tistics were used to evaluate agreement between clinical
and central TMA classifications for ER, PR, and HER2
[20] overall and stratified by concordant/discordant status
between TMA cores. Statistical analyses were conducted
using STATA version 13.1 software (StataCorp, College
Station, TX, USA).Results
Frequency of intratumoral ER, PR, and HER2
heterogeneity
Among 1085 cases of invasive breast cancer, cases with
discordant biomarker status between TMA cores num-
bered 100 (9 %) for ER, 169 (16 %) for PR, and (18 %)
for HER2. We conducted a manual review of all discord-
ant biomarker-positive cases (46 discordant ER-positive
cases, 94 discordant PR-positive cases, and 56 discordant
HER2 cases with at least one positive [3+] core). Figure 1
shows core- and case-level biomarker expression levels
for manually reviewed cases, with individual cases repre-
sented on the x-axis and biomarker expression shown
on the y-axis. Cores from cases with manually confirmed
heterogeneity are denoted with a solid black circle, while
all other cores are denoted with an X. Among discordant
ER-positive cases, 16 (35 % of manually reviewed cases
and 2 % of all 784 ER-positive cases) were manually con-
firmed to be spatially heterogeneous. Of these 16 cases
with manually confirmed ER heterogeneity, 7 had nega-
tive (<1 %) and borderline (≥1 to <10 %) cores (i.e., no
positive [≥10 %] cores) and 9 had both negative (<1 %)
and positive (≥10 %) cores. The frequency of PR hetero-
geneity was higher than that of ER, with 53 (56 % of
manually reviewed cases and 7 % of all 739 PR-positive
cases) manually confirmed to be heterogeneous. Of the
53 cases with manually confirmed PR heterogeneity, 30
had negative (<1 %) and borderline (≥1 to < 10 %) cores
only, while 23 had both negative (<1 %) and positive
(≥10 %) cores. Representative images of ER and PR het-
erogeneity are shown in Figs. 2 and 3.
HER2 heterogeneity was manually confirmed in 31 cases
(55 % of manually reviewed cases, and 21 % of all 148
cases with at least one 3+ core). A representative image of
HER2 heterogeneity is shown in Fig. 2. Of these 31 cases
with spatially heterogeneous HER2 expression, 19 were
comprised of both 2+ and 3+ cores (i.e., no 0/1+ cores); 7
were comprised of both 0/1+ and 3+ cores (i.e., no 2+
cores); and 5 were comprised of 0/1+, 2+, and 3+ cores.
When equivocal cores were excluded and only cases with
both negative (0/1+) and positive (3+) cores were classi-
fied as heterogeneous (n = 12), the frequency of HER2 het-
erogeneity was similar to that of PR (21 % of manually
reviewed cases, and 8 % of all cases with at least one 3+
core). Very few cases had simultaneous manually con-
firmed heterogeneity of multiple biomarkers; one case
had heterogeneous expression of both ER and PR,
and five cases had heterogeneous expression of both
PR and HER2.
Identification of confounding factors producing spurious
biomarker heterogeneity
Manual review of discordant biomarker-positive cases
revealed that, in some cases, automated algorithms
Fig. 1 (See legend on next page.)
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Fig. 1 ER, PR, and HER2 expression in cases with discordant biomarker status between cores, restricted to positive (≥1 %) cases for ER and PR and
to cases with at least one 3+ core (≥10 % 3+) for HER2. Individual cases are ordered on the x-axis by case-level biomarker expression level (smaller
solid circles: red = negative, blue = borderline/equivocal, green = positive). Individual cores for each case are represented by solid black circles for
cases with manually confirmed heterogeneity or by X’s for cases without manually confirmed heterogeneity. ER estrogen receptor, HER2 human
epidermal growth receptor 2, PR progesterone receptor
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nign epithelium and/or ductal carcinoma in situ (DCIS)
(Fig. 4). Admixture of biomarker-positive DCIS in a
background of biomarker-negative invasive carcinoma
was particularly relevant in the assessment of HER2 het-
erogeneity. Various types of technical artefacts (such as
foreign material or cytoplasmic staining) also led to
false-positive automated scores. In some cases with
lower tumor cellularity, the automated image analysis
algorithm underestimated the number of biomarker-
negative cells, producing falsely elevated expression
levels. However, this source of technical error affected
only tumors with expression levels that were very close
to the threshold used to define biomarker status.
Impact of tumor sampling on frequency of ER, PR, and
HER2 discordance
We next sought to identify factors that could be used to
identify cases with increased likelihood of manually con-
firmed intratumoral heterogeneity. To identify causes of
biomarker discordance and to identify criteria forFig. 2 Representative images of cases with manually confirmed heterogen
same case. The percentage of ER- and PR-positive cells or HER2 status is in
heterogeneity. ER estrogen receptor, HER2 human epidermal growth recepprioritizing manual review, we focused on all cases with
discordant biomarker status between cores and not just
on manually reviewed cases. We found that cases with
discordant ER and PR status between cores had signifi-
cantly lower median tumor cellularity, but that tumor
cellularity was similar in cases with concordant and dis-
cordant HER2 status (Table 1). The frequency of dis-
cordant biomarker status between cores was not
significantly impacted by the number of TMA cores per
case for ER or PR. HER2 discordance rates differed
somewhat by number of cores per case, but there was
no clear pattern of association (Table 1).
Impact of discordant biomarker status between cores on
agreement with the clinical record
Overall, agreement between central TMAs and the clin-
ical record was substantial for ER (94 %) and PR (89 %;
Table 2). However, ER and PR agreement with the clin-
ical record was lower among cases with discordant ER
and PR status between cores (70 % and 61 %, respect-
ively). Conversely, clinical record agreement was veryeous expression of ER, PR, and HER2 between any two cores from the
dicated for each core. The starred cores illustrate examples of intracore
tor 2, PR progesterone receptor
Fig. 3 Representative images of ER staining in four cores and the tissue section from which they were removed, in a case with manually
confirmed heterogeneous ER expression. Note the variability in staining across the whole tissue section, which is reflected in the variable
expression levels in the four cores. ER estrogen receptor
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all TMA cores for a given case (96 % and 95 %, respect-
ively; Table 2). For HER2, overall agreement was high
(88 %), but was reduced among cases with discordant
HER2 status (57 %). When analysis was restricted to
cases with concordant HER2 status across all TMA
cores, agreement was similar to that for cases with con-
cordant ER and PR status (96 %; Table 2).
Discussion
Intratumoral biomarker heterogeneity may pose a challenge
for accurate classification of breast cancer, with implica-
tions both for clinical decision making and for epidemio-
logic research. However, the frequency and sources of
intratumoral ER, PR, and HER2 heterogeneity have not
been well-characterized, particularly in population-based
studies. Using TMAs comprising multiple cores per case,
we observed that cases with discordant biomarker statusbetween cores by automated digital image analysis had re-
duced agreement with the clinical record. Manual review of
discordant cases revealed that 35–56 % of discordant bio-
marker status between cores was caused by spatially hetero-
geneous expression of ER, PR, and HER2, which was
observed in 2 %, 7 %, and 8 % of all biomarker-positive
cases, respectively.
Our findings demonstrate that automated algorithms
cannot reliably distinguish between IHC-stained tumor
and nontumor cells. Therefore, admixture of tumor and
DCIS and/or benign epithelium can potentially lead to
tumor biomarker misclassification by automated analysis
if biomarker status is discordant between tumor and
nontumor tissues. Synchronous DCIS and invasive can-
cers typically share tumor characteristics and hormone
receptor status [21]. However, HER2-positive DCIS
within an HER2-negative invasive tumor has been ob-
served [22], and this may pose a challenge for the use of
Fig. 4 Representative images of cases with discordant ER, PR, and HER2 status between any two cores from the same case due to presence of benign
epithelium (arrows for ER, PR) and clinging ductal carcinoma in situ (HER2). Percentage of ER- and PR-positive cells or HER2 status is indicated for each
core. ER estrogen receptor, HER2 human epidermal growth receptor 2, PR progesterone receptor
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invasive carcinomas. In addition, admixed benign epithe-
lium, which often expresses both ER and PR, can pro-
duce false positivity in hormone receptor-negative
tumors. However, we previously showed that computing
average biomarker expression across cores after weight-
ing cores by tumor cellularity diminishes the influence
of small discordant regions and produces high agree-
ment (≥88 % for all biomarkers) with the clinical record.
Intratumoral ER heterogeneity has previously been
suggested to be a rare phenomenon [23], although the
frequency in a population-based setting has not beenTable 1 Tumor sampling characteristics of cases with estrogen rece
factor receptor 2 discordance between tissue microarray cores in ph
ER PR
n (%) Conc
(n = 985)
Disc
(n = 100)
p Value n (%) Conc
(n = 916
Cellularity,
median (IQR)
1085
(100)
5225
(2846–8869)
3564
(2142–
6074)
<0.001 1085
(100)
5772
(3018–9
Core
number
2 113 (10) 102 (90) 11 (10) 0.978 113 (10) 111 (98)
3 287 (26) 261 (91) 26 (9) 299 (28) 253 (85)
4 685 (63) 622 (91) 63 (9) 673 (61) 560 (83)
Conc concordant biomarker status across all cores for a given case, Disc discordant
receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptoestablished. Using an automated approach to identify
cases with discordant ER status between cores, followed
by manual review, we observed intratumoral heterogen-
eity of ER expression in 2 % of all ER-positive cases.
These results are consistent with prior studies suggesting
that the frequency of intratumoral ER heterogeneity
ranges from 0.5 % to 10 % [23–26]. It has been hypothe-
sized that some intratumoral heterogeneity could be
technical in origin, arising from inadequate sample
fixation, and this may contribute to the higher hetero-
geneity rates reported by some studies. However, differ-
ential rates of heterogeneity across different biomarkersptor, progesterone receptor, and human epidermal growth
ase III of the Carolina Breast Cancer Study
HER2
)
Disc
(n = 169)
p Value n (%) Conc
(n = 889)
Disc
(n = 196)
p Value
851)
3785
(2238–7925)
<0.001 1,085
(100)
7303
(4134–11,329)
8233
(4414–
12,675)
0.282
10 (9) 0.098 106 (10) 87 (82) 19 (18) 0.043
46 (15) 289 (27) 223 (77) 66 (23)
113 (17) 690 (64) 579 (84) 111 (16)
biomarker status between any two cores for a given case, ER estrogen
r
Table 2 Impact of discordant estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status
between cores on agreement between tissue microarrays and the clinical record in phase III of the Carolina Breast Cancer Study
Central TMA Agreement (%) Kappa (95 % CI)
Clinical ER status ER-negative, n (%) ER-positive, n (%)
All cases, n = 1085
ER-negative, n (%) 259 (90) 42 (5) 94 0.84 (0.80–0.87)
ER-positive, n (%) 28 (10) 756 (95)
Concordant, n = 985
ER-negative, n (%) 217 (96) 32 (4) 96 0.89 (0.86–0.92)
ER-positive, n (%) 8 (4) 728 (96)
Discordant, n = 100
ER-negative, n (%) 42 (68) 10 (26) 70 0.39 (0.22–0.57)
ER-positive, n (%) 20 (32) 28 (74)
Clinical PR status PR-negative, n (%) PR-positive, n (%)
All cases, n = 1085
PR-negative, n (%) 305 (80) 41 (6) 89 0.76 (0.72–0.80)
PR-positive, n (%) 75 (20) 664 (94)
Concordant, n = 916
PR-negative, n (%) 246 (91) 27 (4) 95 0.87 (0.83–0.90)
PR-positive, n (%) 23 (9) 620 (96)
Discordant, n = 169
PR-negative, n (%) 59 (53) 14 (24) 61 0.25 (0.12–0.38)
PR-positive, n (%) 52 (47) 44 (76)
Clinical HER2 status Negative Equivocal Positive
All cases, n = 1085
Negative, n (%) 864 (93) 16 (80) 28 (21) 88 0.57 (0.51–0.63)
Equivocal, n (%) 49 (5) 2 (10) 13 (10)
Positive, n (%) 17 (2) 2 (10) 94 (70)
Concordant, n = 889
Negative, n (%) 768 (99) 7 (88) 22 (21) 96 0.78 (0.72–0.84)
Equivocal, n (%) 4 (0) 0 (0) 1 (1)
Positive, n (%) 5 (1) 1 (12) 81 (78)
Discordant, n = 196
Negative, n (%) 96 (63) 9 (75) 6 (19) 57 0.16 (0.07–0.28)
Equivocal, n (%) 45 (29) 2 (17) 12 (39)
Positive, n (%) 12 (8) 1 (8) 13 (42)
Abbreviations: ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, TMA tissue microarray
Concordant cases are those with the same biomarker status across all cores for a given case, while discordant cases are those with discordant biomarker status
between any two cores for a given case
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ultaneous heterogeneity of more than one biomarker
suggest that this may be an unlikely explanation for our
findings. We also show that inadequate tumor sampling
may contribute to biomarker discordance, as tumors
with low cellularity were more likely to have discordant
ER and PR status between cores. This finding supports
our previous research in the AMBER Consortium show-
ing that ER and PR agreement rates between TMAs andthe clinical record were reduced in cases with low tumor
cellularity [17]. Our frequency estimate for intratumoral
PR heterogeneity (7 % of PR-positive cases) appears
lower than that reported previously (approximately 20 %
in two studies [23, 24]). However, one of these prior
studies used whole-tissue slides from a consecutive
series of patients with breast cancer treated in a tertiary
care facility [23], while the other examined agreement
between core needle biopsy and surgical specimens in
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contrast to our present analysis, these prior studies likely
overrepresent a more aggressive set of cancers. If hetero-
geneity is associated with tumor aggressiveness as hy-
pothesized, this could contribute to differences in
frequency across studies.
We observed two types of intratumoral HER2 hetero-
geneity. Cases with equivocal and positive cores formed
the majority, comprising 21 % of cases with at least one
HER2-positive core, while only 8 % of cases with at least
one positive core also had at least one negative core. A
prior study reported the presence of both negative and
positive HER2 regions in only 1 % of 921 cases [27],
while others reported similar or even lower rates of
intratumoral HER2 heterogeneity using IHC analysis
[22, 28]. Researchers in several studies have also reported
very low rates of heterogeneity of HER2 amplification sta-
tus using in situ hybridization techniques [27–29]. How-
ever, in these prior studies, researchers reported the
frequency of HER2 heterogeneity among all cases, and not
just among those with areas of HER2 positivity (defined
by the presence of at least one positive core in our study).
If we had included all cases in our denominator, only 1 %
of all cases would have had both positive and negative
HER2 cores, in line with prior studies [22, 27, 28].
Tumors with spatially distinct areas of high and low
biomarker expression levels may suggest a pattern of
heterogeneity referred to as segregated heterogeneity
[30]. Segregated heterogeneity may be particularly clinic-
ally relevant because antiestrogen or HER2-directed
therapy may apply a selective pressure for outgrowth of
areas lacking the molecular target, with consequences for
the subtype for subsequent disease recurrence [31, 32].
Studies of recurrent tumors, particularly those with a sub-
type distinct from the primary tumor, may be important
for understanding the consequences of intratumoral het-
erogeneity. Similarly, longitudinal studies with quantitative
histology and well-characterized spatial biomarker pat-
terns may help improve understanding of the impact of
intratumoral heterogeneity on breast cancer outcomes. If
intratumoral heterogeneity proves to be a poor prognostic
feature as theorized, identification of demographic and
tumor characteristics associated with intratumoral hetero-
geneity could help to identify patients who may benefit
from more extensive tumor workup and, potentially, more
aggressive therapy. This work is currently underway in the
AMBER Consortium.
This study should be considered in light of some limi-
tations. First, the tumor specimens used for clinical
workup may have been biopsy specimens or separate
blocks from those used to construct central TMAs, and
therefore it is possible that the clinical record and the
central results represent distinct tumor regions. How-
ever, different origins of tumor specimens would be arandom source of error, unlikely to bias our findings
away from the null. Second, even multiple 1.0-mm TMA
cores represent only a small portion of the entire tumor,
and therefore it is possible that we underestimated the
frequency of intratumoral heterogeneity in the present
study. However, our rates of intratumoral heterogeneity
are similar to those reported previously. Finally, due to
tumor sampling at the time of breast cancer surgery, we
were unable to assess temporal intratumoral heterogen-
eity in this study. Despite the theoretical importance of
temporal heterogeneity [32], spatial heterogeneity at the
time of tumor excision is arguably the most relevant for
clinical management of breast cancer.
These limitations are balanced by several important
strengths. Since automated staining of TMAs is becom-
ing more widely used [17, 33], we assessed automated
evidence of intratumoral heterogeneity (i.e., biomarker
discordance between TMA cores), and our results can
therefore be used to guide manual review. Our auto-
mated image analysis methods are well-validated and
produce very high agreement with manual scoring of
TMAs in CBCS [17]. The analysis of the population-
based CBCS ensured excellent representation of both
African American and non-African American cases in
this study, and we were able to infer that race does not
strongly influence rates of intratumoral heterogeneity. In
addition, procurement of tissue from multiple clinical
centers, representing community-based and referral cen-
ters, ensured that our study was not biased toward more
aggressive cancers commonly seen in referral centers.
Given that clinical biomarker status was measured at
multiple different laboratories and according to multiple
protocols, the substantial rates of agreement between
central TMA results and the clinical record provide re-
assurance that ER, PR, and HER2 staining are well-
standardized across clinical care settings.
Conclusions
Our findings demonstrate that the presence of admixed
benign epithelium and/or DCIS in TMA cores can cause
biomarker misclassification when using automated
methods to quantify IHC staining. However, manually
confirmed intratumoral heterogeneity accounted for ap-
proximately half of all cases with core-to-core discord-
ance in biomarker status on TMAs. These results
suggest that intratumoral heterogeneity may contribute
to discordance in ER, PR, and HER2 status, with pos-
sible implications for breast cancer subtype classifica-
tion. The low frequency of intratumoral heterogeneity
underscores the robustness of ER and HER2 for guiding
targeted treatment. Future work, likely with large studies
or consortia, is required to identify risk factors for intra-
tumoral heterogeneity and to determine its impact on
treatment response.
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